Cargando…

Report on planning comparison of VMAT, IMRT and helical tomotherapy for the ESCALOX-trial pre-study

BACKGROUND: The ESCALOX trial was designed as a multicenter, randomized prospective dose escalation study for head and neck cancer. Therefore, feasibility of treatment planning via different treatment planning systems (TPS) and radiotherapy (RT) techniques is essential. We hypothesized the comparabi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pigorsch, Steffi U., Kampfer, Severin, Oechsner, Markus, Mayinger, Michael C., Mozes, Petra, Devecka, Michal, Kessel, Kerstin K., Combs, Stephanie E., Wilkens, Jan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607845/
https://www.ncbi.nlm.nih.gov/pubmed/33138837
http://dx.doi.org/10.1186/s13014-020-01693-2
_version_ 1783604724564492288
author Pigorsch, Steffi U.
Kampfer, Severin
Oechsner, Markus
Mayinger, Michael C.
Mozes, Petra
Devecka, Michal
Kessel, Kerstin K.
Combs, Stephanie E.
Wilkens, Jan J.
author_facet Pigorsch, Steffi U.
Kampfer, Severin
Oechsner, Markus
Mayinger, Michael C.
Mozes, Petra
Devecka, Michal
Kessel, Kerstin K.
Combs, Stephanie E.
Wilkens, Jan J.
author_sort Pigorsch, Steffi U.
collection PubMed
description BACKGROUND: The ESCALOX trial was designed as a multicenter, randomized prospective dose escalation study for head and neck cancer. Therefore, feasibility of treatment planning via different treatment planning systems (TPS) and radiotherapy (RT) techniques is essential. We hypothesized the comparability of dose distributions for simultaneous integrated boost (SIB) volumes respecting the constraints by different TPS and RT techniques. METHODS: CT data sets of the first six patients (all male, mean age: 61.3 years) of the pre-study (up to 77 Gy) were used for comparison of IMRT, VMAT, and helical tomotherapy (HT). Oropharynx was the primary tumor location. Normalization of the three step SIB (77 Gy, 70 Gy, 56 Gy) was D95% = 77 Gy. Coverage (CVF), healthy tissue conformity index (HTCI), conformation number (CN), and dose homogeneity (HI) were compared for PTVs and conformation index (COIN) for parotids. RESULTS: All RT techniques achieved good coverage. For SIB77Gy, CVF was best for IMRT and VMAT, HT achieved highest CN followed by VMAT and IMRT. HT reached good HTCI value, and HI compared to both other techniques. For SIB70Gy, CVF was best by IMRT. HTCI favored HT, consequently CN as well. HI was slightly better for HT. For SIB56Gy, CVF resulted comparably. Conformity favors VMAT as seen by HTCI and CN. Dmean of ipsilateral and contralateral parotids favor HT. CONCLUSION: Different TPS for dose escalation reliably achieved high plan quality. Despite the very good results of HT planning for coverage, conformity, and homogeneity, the TPS also achieved acceptable results for IMRT and VMAT. Trial registration ClinicalTrials.gov Identifier: NCT 01212354, EudraCT-No.: 2010-021139-15. ARO: ARO 14-01
format Online
Article
Text
id pubmed-7607845
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-76078452020-11-03 Report on planning comparison of VMAT, IMRT and helical tomotherapy for the ESCALOX-trial pre-study Pigorsch, Steffi U. Kampfer, Severin Oechsner, Markus Mayinger, Michael C. Mozes, Petra Devecka, Michal Kessel, Kerstin K. Combs, Stephanie E. Wilkens, Jan J. Radiat Oncol Research BACKGROUND: The ESCALOX trial was designed as a multicenter, randomized prospective dose escalation study for head and neck cancer. Therefore, feasibility of treatment planning via different treatment planning systems (TPS) and radiotherapy (RT) techniques is essential. We hypothesized the comparability of dose distributions for simultaneous integrated boost (SIB) volumes respecting the constraints by different TPS and RT techniques. METHODS: CT data sets of the first six patients (all male, mean age: 61.3 years) of the pre-study (up to 77 Gy) were used for comparison of IMRT, VMAT, and helical tomotherapy (HT). Oropharynx was the primary tumor location. Normalization of the three step SIB (77 Gy, 70 Gy, 56 Gy) was D95% = 77 Gy. Coverage (CVF), healthy tissue conformity index (HTCI), conformation number (CN), and dose homogeneity (HI) were compared for PTVs and conformation index (COIN) for parotids. RESULTS: All RT techniques achieved good coverage. For SIB77Gy, CVF was best for IMRT and VMAT, HT achieved highest CN followed by VMAT and IMRT. HT reached good HTCI value, and HI compared to both other techniques. For SIB70Gy, CVF was best by IMRT. HTCI favored HT, consequently CN as well. HI was slightly better for HT. For SIB56Gy, CVF resulted comparably. Conformity favors VMAT as seen by HTCI and CN. Dmean of ipsilateral and contralateral parotids favor HT. CONCLUSION: Different TPS for dose escalation reliably achieved high plan quality. Despite the very good results of HT planning for coverage, conformity, and homogeneity, the TPS also achieved acceptable results for IMRT and VMAT. Trial registration ClinicalTrials.gov Identifier: NCT 01212354, EudraCT-No.: 2010-021139-15. ARO: ARO 14-01 BioMed Central 2020-11-02 /pmc/articles/PMC7607845/ /pubmed/33138837 http://dx.doi.org/10.1186/s13014-020-01693-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Pigorsch, Steffi U.
Kampfer, Severin
Oechsner, Markus
Mayinger, Michael C.
Mozes, Petra
Devecka, Michal
Kessel, Kerstin K.
Combs, Stephanie E.
Wilkens, Jan J.
Report on planning comparison of VMAT, IMRT and helical tomotherapy for the ESCALOX-trial pre-study
title Report on planning comparison of VMAT, IMRT and helical tomotherapy for the ESCALOX-trial pre-study
title_full Report on planning comparison of VMAT, IMRT and helical tomotherapy for the ESCALOX-trial pre-study
title_fullStr Report on planning comparison of VMAT, IMRT and helical tomotherapy for the ESCALOX-trial pre-study
title_full_unstemmed Report on planning comparison of VMAT, IMRT and helical tomotherapy for the ESCALOX-trial pre-study
title_short Report on planning comparison of VMAT, IMRT and helical tomotherapy for the ESCALOX-trial pre-study
title_sort report on planning comparison of vmat, imrt and helical tomotherapy for the escalox-trial pre-study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607845/
https://www.ncbi.nlm.nih.gov/pubmed/33138837
http://dx.doi.org/10.1186/s13014-020-01693-2
work_keys_str_mv AT pigorschsteffiu reportonplanningcomparisonofvmatimrtandhelicaltomotherapyfortheescaloxtrialprestudy
AT kampferseverin reportonplanningcomparisonofvmatimrtandhelicaltomotherapyfortheescaloxtrialprestudy
AT oechsnermarkus reportonplanningcomparisonofvmatimrtandhelicaltomotherapyfortheescaloxtrialprestudy
AT mayingermichaelc reportonplanningcomparisonofvmatimrtandhelicaltomotherapyfortheescaloxtrialprestudy
AT mozespetra reportonplanningcomparisonofvmatimrtandhelicaltomotherapyfortheescaloxtrialprestudy
AT deveckamichal reportonplanningcomparisonofvmatimrtandhelicaltomotherapyfortheescaloxtrialprestudy
AT kesselkerstink reportonplanningcomparisonofvmatimrtandhelicaltomotherapyfortheescaloxtrialprestudy
AT combsstephaniee reportonplanningcomparisonofvmatimrtandhelicaltomotherapyfortheescaloxtrialprestudy
AT wilkensjanj reportonplanningcomparisonofvmatimrtandhelicaltomotherapyfortheescaloxtrialprestudy